The Doctrine of Equivalents in the United States and Selected European Forums
Executive Summary: Patent protection in the United States, the United Kingdom, Germany, and the Unified Patent Court can extend beyond the ordinary meaning of the claims, but the governing tests and limits differ by forum. This article organizes the comparison around three questions: whether the accused variant is technically equivalent, whether the patentee’s drafting or prosecution choices make that coverage legally unavailable, and whether extending protection would undermine public notice or capture prior art. U.S. law addresses these concerns through limitation-specific proof and distinct doctrines of prosecution history estoppel, disclosure-dedication, and ensnarement. The European forums examined address comparable concerns through claim interpretation, strict compliance, claim-oriented equivalence, and the UPC’s developing inquiries into fair protection and legal certainty. The related pemetrexed decisions illustrate how similar technical substitutions require different legal analyses depending on the claims, prosecution records, and procedural posture. For drafting, prosecution, and freedom-to-operate work, the central lesson is that technical interchangeability alone cannot determine scope: counsel must connect the disputed substitution to the patent record and the governing forum’s rules.
Introduction
A competitor changes the salt used in a pharmaceutical formulation, replaces a one-piece cover with a two-piece assembly, or operates just outside a claimed numerical range. Each change may fall outside the ordinary meaning of a patent claim. Whether it avoids infringement requires a further inquiry into equivalents, and that inquiry can produce different answers for corresponding patents in different jurisdictions.
U.S. law and the European forums examined here recognize that meaningful protection sometimes reaches an implementation outside the claim's ordinary meaning. They also protect the public's ability to rely on what the applicant actually claimed. The difficult cases arise where those interests meet: an alternative performs the same technical role, but the applicant selected narrower language, abandoned related claims, or disclosed the alternative without claiming it. Recent U.S. decisions show how readily prosecution and disclosure can decide such disputes before a court reaches technical equivalence. European decisions examine many of the same concerns through different doctrinal structures.
This comparison focuses on the United States, the United Kingdom, Germany, and the Unified Patent Court. The United Kingdom and Germany illustrate established national approaches, while the UPC supplies a separate judicial forum for patents within its jurisdiction. Identifying that forum is an essential first step. A European patent does not carry one universally applicable judicial test for equivalents. This article uses equivalents as a comparative label, without suggesting that these courts apply a single transnational doctrine. A variant means the accused feature that departs from the claim's ordinary meaning.
Across the jurisdictions examined, equivalents disputes turn on three inquiries that should not be collapsed: whether the accused variant is technically equivalent at the level of the disputed claim feature; whether the patentee's drafting, disclosure, or prosecution choices make that coverage legally unavailable; and whether extending protection would impair reasonable public notice or capture the prior art. The doctrinal labels and the weight assigned to those inquiries differ by forum. Keeping them separate explains why convincing evidence of technical interchangeability can establish infringement in one dispute yet fail to secure protection in another.
The United States framework and the need for specific proof
The modern U.S. doctrine rests on Graver Tank, Warner-Jenkinson, and Festo. In Graver Tank, the Supreme Court recognized that an insubstantial substitution could infringe despite falling outside the claim language. Equivalence depends on the patent, the prior art, and the circumstances, including whether skilled artisans would have understood the interchangeability of the claimed and substituted features. Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605, 608–09 (1950).
Warner-Jenkinson placed the inquiry firmly at the level of individual claim limitations. Similarity between the products as a whole is insufficient. Under the all-elements rule, each limitation must be met literally or by an equivalent, and the doctrine cannot effectively eliminate a limitation. Function, way, and result provide one framework; insubstantial differences provide another. The appropriate formulation depends on the technology and the facts. Equivalence is assessed at the time of infringement, which can make later-developed substitutes relevant. Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 29, 37, 39–40 (1997).
Those principles distinguish the doctrine from an argument that the accused product captures the patent's general idea. A sensor system and an accused product might both detect unsafe posture, for example, while obtaining and processing the relevant measurements in materially different ways. A persuasive equivalents theory must identify the particular substitution and explain why its technical differences are insubstantial in the context of the claim.
Section 112(f) incorporates a distinct statutory-equivalence inquiry into literal infringement. An accused structure must perform the identical claimed function and be the same as or equivalent to the corresponding structure disclosed in the specification. The general doctrine of equivalents is a separate nonliteral-infringement inquiry conducted after claim construction. 35 U.S.C. § 112(f); Warner-Jenkinson, 520 U.S. at 27–28; Odetics, Inc. v. Storage Tech. Corp., 185 F.3d 1259, 1266–67 (Fed. Cir. 1999).
Recent Federal Circuit decisions give that evidentiary requirement considerable force. In the 2023 VLSI decision, the court reversed an equivalents-based infringement finding because the patentee's evidence did not adequately connect the claimed arrangement to the accused arrangement. The required particularized testimony and linking argument could not be replaced by a generalized assertion of similarity. VLSI Tech. LLC v. Intel Corp., 87 F.4th 1332, 1342–45 (Fed. Cir. 2023).
NexStep reinforced the point. The court affirmed judgment as a matter of law overturning a jury's equivalents verdict where the evidence inadequately identified and explained the accused equivalent to a single-action limitation. NexStep, Inc. v. Comcast Cable Commc’ns, LLC, 119 F.4th 1355, 1370–71, 1373 (Fed. Cir. 2024). The majority rejected a categorical relaxation of the proof requirement merely because the technology was easy to understand. The evidence must supply the actual comparison rather than merely repeat the function–way–result formulation. NexStep, No. 2022-1815, slip op. at 35–38.
The converse is also important. Courts cannot dispose of equivalence simply by labeling the claimed and accused features opposites. In Edgewell, the Federal Circuit rejected a binary treatment of a single-component structure and a multicomponent structure. The question was whether the evidence would permit a reasonable jury to find the relevant technical differences insubstantial. Vitiation describes the legal insufficiency of a particular theory; it does not make every literal difference an automatic defense. Edgewell Pers. Care Brands, LLC v. Munchkin, Inc., 998 F.3d 917, 923–25 (Fed. Cir. 2021).
Claim construction must therefore precede the equivalents analysis. In a separate 2026 VLSI appeal, the Federal Circuit reversed summary judgment rejecting an equivalents theory for certain apparatus claims. The district court had imported an order-of-operations restriction through prosecution disclaimer, although the prosecution statements did not clearly and unmistakably impose that restriction on those claims. The decision restored the theory for further proceedings; it did not establish infringement. It also illustrates the need to distinguish prosecution disclaimer, which informs claim meaning, from prosecution history estoppel, which can bar an otherwise available equivalents theory. VLSI Tech. LLC v. Intel Corp., No. 2024-1772, slip op. at 9–12 (Fed. Cir. Apr. 14, 2026).
How prosecution, disclosure, and prior art constrain U.S. equivalents
Technical equivalence cannot overcome every consequence of obtaining a patent. Under Festo, a narrowing amendment made for a reason related to patentability presumptively surrenders the territory between the original and amended limitations. The patentee may rebut the presumption for the particular equivalent by establishing unforeseeability, a relationship only tangential to the amendment's rationale, or another reason why the substitute could not reasonably have been described. Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 736–41 (2002). For tangentiality, the amendment's objective rationale must be discernible from the prosecution record. Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 344 F.3d 1359, 1369–70 (Fed. Cir. 2003) (en banc).
The 2026 Actelion decision illustrates a narrowing amendment that barred the asserted equivalent. The applicant narrowed a bulk-solution pH limitation from greater than 12 to 13 or higher after the examiner tied patentability to unexpected results at the higher threshold. The court rejected the argument that the amendment was merely tangential to a lower-pH equivalent. Asserted similarity in chemical performance did not change the objective reason for the narrowing. Actelion Pharms. Ltd. v. Mylan Pharms. Inc., No. 2024-1641, slip op. at 15–17 (Fed. Cir. May 13, 2026). Counsel should ask whether the substitute reintroduces the patentability distinction.
Estoppel can also arise without an amendment to the asserted claim. In Amgen v. Coherus, prosecution arguments clearly and unmistakably surrendered unclaimed salt combinations. Statements distinguishing prior art therefore warrant the same attention as the marked changes to the claims. Amgen Inc. v. Coherus BioSciences Inc., 931 F.3d 1154, 1159–61 (Fed. Cir. 2019).
Colibri shows that cancellation of a different claim may create estoppel when the canceled and retained claims are closely related and the patentee's own equivalence theory supplies the substantive linkage. The applicant canceled a retracting claim after a written-description rejection while retaining a pushing claim. Given the relationship between those claims and the asserted equivalent, the Federal Circuit held the theory barred. An unchanged asserted claim therefore does not necessarily escape amendment-based estoppel. Colibri Heart Valve LLC v. Medtronic CoreValve, LLC, 143 F.4th 1367, 1379, 1381 (Fed. Cir. 2025).
Disclosure creates another, independent limitation. Under the disclosure-dedication doctrine, an applicant may be unable to recover through equivalents an alternative that the patent sufficiently identifies but leaves unclaimed. Johnson & Johnston Assocs. Inc. v. R.E. Serv. Co., 285 F.3d 1046, 1054 (Fed. Cir. 2002) (en banc). Eagle Pharmaceuticals applied that rule where the specification disclosed ethanol as an alternative to the claimed propylene glycol. The alternative did not have to appear in an embodiment identical in every other respect to the claimed embodiment. Eagle Pharms. Inc. v. Slayback Pharma LLC, 958 F.3d 1171, 1175–77 (Fed. Cir. 2020).
Actelion applied disclosure-dedication independently of estoppel. The specification disclosed broader, overlapping pH ranges that included unclaimed lower values. The court rejected the suggestion that dedication requires mutually exclusive alternatives. Overlap does not prevent a skilled reader from identifying disclosed subject matter outside the issued claims. Estoppel and dedication independently defeated the theory; overcoming either ground alone would not have saved it. Actelion, No. 2024-1641, slip op. at 17–18.
Finally, the doctrine cannot ensnare the prior art. The hypothetical-claim approach has its foundation in Wilson Sporting Goods. Wilson Sporting Goods Co. v. David Geoffrey & Assocs., 904 F.2d 677, 683–85 (Fed. Cir. 1990). Jang v. Boston Scientific illustrates the importance of that separate constraint even after a jury finds equivalence. In a hypothetical-claim analysis, the patentee must establish that a properly framed claim broad enough to cover the accused implementation would be patentable over the prior art; the court need not construct that claim for the patentee. Jang v. Bos. Sci. Corp., 872 F.3d 1275, 1285–90 (Fed. Cir. 2017).
These doctrines answer different questions. Estoppel concerns surrender during prosecution. Disclosure-dedication concerns an identifiable alternative left unclaimed. Ensnarement concerns the public's right to practice the prior art. A sound analysis addresses each separately rather than treating technical similarity as the final inquiry.
The European framework and the importance of the forum
Article 69 of the European Patent Convention determines the extent of protection by reference to the claims, interpreted using the description and drawings. Its Protocol rejects both strict literalism and an approach that treats claims as no more than a guide to whatever the proprietor contemplated. Article 2 expressly requires consideration of equivalent elements. Convention on the Grant of European Patents art. 69, Oct. 5, 1973, 1065 U.N.T.S. 199, as revised Nov. 29, 2000 [hereinafter EPC]. Protocol on the Interpretation of Article 69 EPC arts. 1–2, Oct. 5, 1973, as revised Nov. 29, 2000.
That common foundation does not supply a detailed, uniform infringement formula. The EPO's examination and opposition functions must be distinguished from infringement adjudication. Article 64(3) refers infringement to national law, while the UPC Agreement establishes the court's competence and applicable sources of law for patents within its jurisdiction. The agreement also preserves specified national-court options during the transitional period. EPC art. 64(3). Agreement on a Unified Patent Court arts. 3, 24, 32, 83, Feb. 19, 2013, 2013 O.J. (C 175) 1.
For a multinational patent family, the resulting task is to identify the actual patent, granted claims, territory, and court before applying an equivalents test. An argument accepted in one national proceeding may be informative elsewhere, but its significance depends on the other forum's approach and the record before it. Shared terminology can obscure differences in what the skilled person is assumed to know and how much weight the court gives to the applicant's choices.
The United Kingdom approach after Actavis
Actavis v. Eli Lilly separated normal interpretation from immaterial-variant infringement. Its three questions concern substantially the same result in substantially the same way; whether the informed skilled reader would find it obvious that the variant achieves the result in substantially the same way; and whether strict compliance was essential. The answers must be yes, yes, and no. Actavis UK Ltd. v. Eli Lilly & Co., [2017] UKSC 48, [54]–[56], [66] (appeal taken from Eng.).
Icescape applied the approach to a folding ice-rink system. Parallel connections performed equivalently to the claimed series connections, and deletion of another claim did not unambiguously surrender that coverage. The patent nevertheless remained invalid because loss of priority exposed it to Ice-World's intervening prior uses. Icescape Ltd. v. Ice-World International BV, [2018] EWCA Civ 2219, [3]–[4], [43]–[44], [70]–[80], [90] (Eng.).
The contrast with Colibri is instructive without implying that the courts decided identical facts differently. Both cases required attention to canceled claims. Their treatment depended on different prosecution records and different legal rules. A practitioner should therefore investigate the substance of a cancellation before transferring an assessment from one jurisdiction to another.
Prosecution history has a limited role. Icescape applied the exceptional-use approach established in Actavis: the file may resolve genuine uncertainty unambiguously or establish that disregarding it would offend the public interest. Routine resort to prosecution correspondence is inappropriate. Icescape, [2018] EWCA Civ 2219, [77]–[80].
Germany and the relationship between the substitute and the claim
German equivalents analysis asks whether the modified means achieves the relevant same effect, whether the skilled person can identify it using specialist knowledge, and whether the reasoning remains sufficiently oriented to the technical teaching of the claims to regard the substitute as equivalent. The third requirement constrains an analysis based only on a shared technical objective. Numerical limitations are not categorically immune from equivalents, but the analysis must preserve the technical significance of the specified boundary. Equivalent overall performance does not by itself answer that question. Bundesgerichtshof [BGH] [Federal Court of Justice], Mar. 12, 2002, X ZR 168/00, 150 Entscheidungen des Bundesgerichtshofes in Zivilsachen [BGHZ] 149, 154–59 (Ger.) (Schneidmesser I) (German-language decision reproduced in WIPO Lex).
Germany's Formstein defense supplies a further limit: protection by equivalents cannot capture an accused embodiment that would be unpatentable over the prior art. That defense is a useful comparison with U.S. ensnarement, although the procedural settings differ. BGH, Apr. 29, 1986, X ZR 28/85, 98 BGHZ 12 (Ger.) (Formstein) (German-language headnote reproduced in WIPO Lex).
For counsel evaluating a substitution, the German approach directs attention to how the skilled person would arrive at the alternative from the claimed teaching. Technical evidence that a replacement performs the same broad function may leave that part of the analysis unanswered. The specification should therefore explain the relevant relationships among embodiments rather than merely list interchangeable components.
Pemetrexed as a controlled transatlantic comparison
The pemetrexed litigation supplies a concrete comparison of technical equivalence, the applicant's choices, and public notice. The disputes concerned related protection for administering pemetrexed with vitamin supplementation. The comparison is controlled in that it follows a common invention and substitution problem. It does not assume identical claim forms, accused products, prosecution records, or procedural outcomes.
In the United States, representative claim 12 of Patent No. 7,772,209 required administration of pemetrexed disodium following specified vitamin supplementation. Hospira and Dr. Reddy's proposed pemetrexed ditromethamine. Eli Lilly & Co. v. Hospira, Inc., 933 F.3d 1320, 1325, 1327 (Fed. Cir. 2019). The specification referred to a patent describing a broader antifolate genus, but did not identify the disputed ditromethamine treatment sufficiently to dedicate it. Hospira, 933 F.3d at 1334–35. The parent application's amendment from antifolate to pemetrexed disodium distinguished methotrexate prior art. The Federal Circuit treated the salt difference as tangential to that reason. Id. at 1331–34. It upheld equivalence based on delivery of the same active anion through aqueous intravenous administration. Id. at 1335–36. The court affirmed both equivalents judgments, while reversing the literal-infringement ruling against Hospira. Id. at 1336.
The UK and German proceedings concerned claim 1 of European Patent No. 1 313 508, a Swiss-type claim directed to use of pemetrexed disodium to manufacture a medicament for tumor-inhibiting combination therapy with vitamin B12 or specified derivatives. BGH, June 14, 2016, X ZR 29/15, 211 BGHZ 1, ¶ 1 (Ger.) (Pemetrexed I) (German-language decision reproduced in WIPO Lex). The European prosecution narrowed antifolates to pemetrexed following sufficiency and clarity objections, then to disodium after an added-matter objection. That sequence did not preclude the UK variants. Actavis, [2017] UKSC 48, [76]–[80], [89].
Actavis concerned pemetrexed diacid, ditromethamine, and dipotassium. Each delivered the pemetrexed anion with vitamin B12, and disodium was not essential. The variants infringed although outside the claim's normal interpretation. Actavis, [2017] UKSC 48, [8], [58], [68]–[75], [89], [113].
In Germany, Pemetrexed I addressed dipotassium. The description identified disodium as the concrete embodiment within a broader antifolate disclosure. The BGH distinguished selecting one of several expressly disclosed alternatives from claiming a species within a genus: the latter does not necessarily disclose and exclude every other member. It also distinguished narrowing to avoid prior art from changes addressing formal disclosure requirements. Prosecution statements could support the skilled person's understanding without necessarily determining it alone. The court reversed and remanded because equal effect and findability still required factual assessment; it did not finally decide infringement by equivalents. Pemetrexed I, ¶¶ 3, 39–40, 55–72, 89–91.
The temporal perspective also needs care. U.S. technical equivalence is assessed at infringement, whereas unforeseeability as a rebuttal to amendment-based estoppel is assessed when the amendment occurred. Warner-Jenkinson, 520 U.S. at 37. Festo, 344 F.3d at 1369–70. Hospira relied on tangentiality, so unforeseeability was not the operative exception. Hospira, 933 F.3d at 1330–31. Under the second Actavis question, the priority-date reader is told that the variant achieves substantially the same result. Later development therefore does not itself end the inquiry. Actavis, [2017] UKSC 48, [62]–[66]. Recent Düsseldorf Higher Regional Court authority places findability within the skilled person's priority-date knowledge; that proposition should not be converted into a blanket exclusion of every later-developed implementation. Oberlandesgericht Düsseldorf [OLG] [Higher Regional Court], Sept. 12, 2025, 2 U 60/25, ¶¶ 120, 132, 135 (Ger.).
The cases show why chemistry alone cannot decide scope. The U.S. analysis required a separate answer to the presumptive surrender caused by the amendment. The European records required attention to the significance of naming disodium in claims supported by a broader technical disclosure. The different procedural outcomes also matter: an appellate remand does not establish the same proposition as an affirmed infringement judgment. For comparative work, the useful question is which feature of the local record connects technical interchangeability to legally available protection.
Equivalents before the Unified Patent Court
The UPC decisions illustrate a developing approach under Article 69 and its Protocol. In Plant-e, The Hague Local Division adopted four cumulative inquiries: technical equivalence, fair protection for the proprietor, reasonable certainty for third parties, and whether the accused embodiment withstands the relevant prior-art challenge. The fair-protection inquiry included whether the skilled person would appreciate the substitute's application at the time of infringement. The court found equivalence despite separation of the plant roots from the anode compartment in the accused arrangement. Plant-e Knowledge B.V. v. Arkyne Technologies S.L., UPC_CFI_239/2023, ¶¶ 86–88, 97–101 (Unified Pat. Ct., The Hague Loc. Div. Nov. 22, 2024).
Two 2026 decisions applied the same framework with different outcomes. In AIM Sport, the Helsinki Local Division noted the parties' shared reliance on the Plant-e approach and emphasized that its conditions are cumulative. It rejected equivalence because the accused method did not perform the technical function of the disputed feature. AIM Sport Development AG v. TGI Sport Suomi Oy, UPC_CFI_214/2023 & UPC_CFI_403/2025, ¶¶ 170–82 (Unified Pat. Ct., Helsinki Loc. Div. Apr. 29, 2026).
In Wonderland, the Düsseldorf Local Division likewise required a specific explanation of the substituted features. Showing that both stroller mechanisms achieved a stable connection was insufficient. The patentee also failed to establish that the extensive rearrangement would be apparent to the skilled person or compatible with certainty for third parties. The court rejected infringement by equivalents. Wonderland Nurserygoods Co. v. Cybex GmbH, UPC_CFI_807/2024 & UPC_CFI_334/2025, ¶¶ 238–40, 251–55, 263–71 (Unified Pat. Ct., Düsseldorf Loc. Div. May 27, 2026).
The status of those decisions matters. Wonderland recorded that the Court of Appeal had not yet articulated the criteria as of May 27, 2026 and explained that a different test would not have changed the result on the submissions. Id. ¶¶ 236, 240. The published authorities reviewed through September 16, 2026 do not reveal a Court of Appeal decision adopting a uniform test for infringement by equivalence. The framework discussed here remains one developed at first instance.
Related UPC authority also informs how prosecution and disclosure bear on claim scope, without establishing general equivalents-estoppel or disclosure-dedication doctrines. In Belkin, the Court of Appeal recognized that an applicant's prosecution statements may indicate the skilled person's understanding at filing. It considered the amendments and explanations but rejected the defendant's narrower construction. Belkin GmbH v. Koninklijke Philips N.V., UPC_CoA_534/2024, UPC_CoA_19/2025 & UPC_CoA_683/2024, ¶¶ 67–70 (UPC Ct. App. Oct. 3, 2025).
Disclosure also requires attention to context. In Washtower, the claim expressly required an L-shaped metal strip, while the accused retaining strip was plastic. Applying the Plant-e framework at the provisional-measures stage, the local division found infringement by equivalence more likely than not. In addressing reasonable certainty for third parties, it reasoned that the specification's separate discussion of plastic as an alternative cover-plate material did not establish why the retaining member itself had to remain metal. That reasoning does not create a categorical UPC disclosure-dedication rule. Washtower IP B.V. v. Industriebeteiligungs- und Beratungs-GmbH, UPC_CFI_479/2025, ¶¶ 8.1.21–8.1.32 (Unified Pat. Ct., The Hague Loc. Div. Sept. 11, 2025).
For the transatlantic comparison, the feature-specific analysis is especially instructive. A broadly similar commercial outcome did not establish technical equivalence in AIM Sport or Wonderland. That emphasis creates a practical connection with the 2023 VLSI decision and NexStep: the party asserting infringement must explain the disputed substitution rather than rely on a description of the accused product's overall purpose. The courts' doctrinal formulations remain distinct.
Comparative matrix
Selected distinctions as of September 16, 2026. Read with the qualifications and full authorities in the text.
Question | United States | United Kingdom | Germany | UPC |
Basic merits inquiry | Each limitation; insubstantial differences or function–way–result. Warner-Jenkinson, 520 U.S. at 29, 39–40. | Three immaterial-variant questions. Actavis, [2017] UKSC 48, [66]. | Same effect, findability, and claim-oriented equivalence. Schneidmesser I, 150 BGHZ at 154–59. | Four cumulative inquiries concerning equivalence, fair protection, certainty, and prior art. Plant-e, ¶¶ 86–88. |
Temporal perspective | Equivalence at infringement. Warner-Jenkinson, 520 U.S. at 37. Unforeseeability at amendment. Festo, 344 F.3d at 1369–70. | Priority-date reader knows the variant achieves the result; later-developed variants remain eligible. Actavis, [2017] UKSC 48, [62]–[66]. | Recent OLG Düsseldorf authority uses the skilled person's priority-date knowledge for findability. OLG Düsseldorf, 2 U 60/25, ¶¶ 120, 132. | |
Prosecution record | Disclaimer informs claim meaning. VLSI, No. 2024-1772, slip op. at 9–12. Estoppel may bar equivalents. Festo, 535 U.S. at 736–41. | Exceptional use to resolve uncertainty or protect the public interest. Icescape, [2018] EWCA Civ 2219, [77]–[80]. | Narrowing's significance depends on its reason and the claimed teaching. Pemetrexed I, ¶¶ 64–72. | Statements may inform claim construction; distinguish equivalents estoppel. Belkin, ¶¶ 67–70. |
Disclosed but unclaimed | Sufficiently identified alternatives may be dedicated. Johnson & Johnston, 285 F.3d at 1054. | No categorical U.S.-style dedication rule in these authorities; disclosure informs normal interpretation and strict compliance. Actavis, [2017] UKSC 48, [66], [70]–[74]. | Expressly disclosed alternatives differ from unenumerated genus members. Pemetrexed I, ¶¶ 55–63. | Claims and description inform certainty; no categorical dedication rule follows from these cases. Washtower, ¶¶ 8.1.26–8.1.31. |
Relationship to prior art | Ensnarement; hypothetical claim tested against prior art. Wilson Sporting Goods, 904 F.2d at 683–85. | These authorities add no separate hypothetical-claim or Formstein step. Icescape separately addressed priority and consequent invalidity from intervening prior use. Icescape, [2018] EWCA Civ 2219, [3]–[4], [43]–[44], [90]. | Formstein defense against an unpatentable equivalent embodiment. Formstein, 98 BGHZ 12. | Fourth Plant-e condition tests the accused embodiment against prior art. Plant-e, ¶¶ 88, 101. |
Institutional status | Established Supreme Court and Federal Circuit framework. | Established national approach following Actavis. | Established national approach. | Developing first-instance framework; appellate status qualified in the text. |
The comparison reveals differences in doctrinal structure that a simple ranking of protection would miss. U.S. law generally treats prosecution history estoppel, disclosure-dedication, and ensnarement as distinct constraints layered onto a limitation-specific technical inquiry. The United Kingdom, Germany, and the UPC distribute comparable public-notice concerns through normal interpretation, strict-compliance or claim-oriented-equivalence questions, separate prior-art defenses, and fair-protection or legal-certainty inquiries. The forums thus address related policy questions at different stages of the analysis.
Applying the comparison to drafting and design around decisions
Consider first a mechanical substitution. A patent claims a one-piece cover, while the accused product uses two cooperating pieces. In the United States, Edgewell prevents the words one and two from resolving the issue automatically, but NexStep requires a concrete explanation of the accused substitute and its operation. The UK analysis turns on the Actavis questions. In Germany, the proposed substitute must remain connected to the technical teaching of the claims. Before the UPC, the developing first-instance framework also requires fair protection, legal certainty, and compliance with its prior-art condition. The same engineering report may assist each inquiry, but it will need to answer different legal questions.
A numerical substitution presents a different set of risks. Suppose a competitor operates below an issued threshold that the applicant introduced to distinguish the prior art. Before commissioning an extensive performance comparison, U.S. counsel should examine the amendment's objective rationale, as Actelion illustrates, and separately check whether the specification identifies the unclaimed range. Counsel applying the relevant UK, German, or UPC framework should assess what the threshold communicates under that forum's approach to claim interpretation and equivalents. Calling the numerical difference small says little about whether the applicant made that boundary legally significant.
A chemical substitution can raise all of these issues at once. The pemetrexed litigation demonstrates the value of identifying precisely what changed and why the patent selected the recited compound. The disputed difference may concern an incidental salt form, a pharmacologically significant property, or subject matter excluded during prosecution. An equivalents opinion should connect the chemistry to those specific questions rather than assume that a common active moiety establishes infringement.
For drafting, the first objective remains supported claim language that captures commercially relevant implementations directly. Generic claims, supported alternatives, and narrower dependent claims can reduce dependence on later equivalents litigation. The specification should explain why alternatives achieve the relevant technical effect and identify differences that could matter. In the United States, expressly identifying alternatives without claiming them may also create disclosure-dedication risk. Drafting should support meaningful breadth without assuming that every disclosed substitute can later be recovered through equivalents. Johnson & Johnston, 285 F.3d at 1054.
Disclosure and claiming decisions should be reviewed together as prosecution progresses. An alternative included to support future amendments may become commercially important after the initial claims narrow. Counsel should consider whether additional claims, a U.S. continuation, or an available divisional filing can pursue that subject matter within the applicable disclosure and procedural limits. Equivalents should not be assumed to recover everything a narrowed claim omits.
Prosecution explanations should accurately identify the reason for each amendment and avoid unnecessary statements about the invention as a whole. A position advanced for one claim should not casually characterize every independent claim as having the same restriction. Canceled claims also belong in the review. A clean copy of the issued claims will not reveal the issue that proved dispositive in Colibri.
Conclusion
For freedom-to-operate work, the analysis should follow the three inquiries introduced here: identify the feature-level technical substitution; determine whether drafting, disclosure, or prosecution makes the proposed coverage legally unavailable; and test the resulting scope against public-notice and prior-art constraints. Corresponding patents deserve individual analysis because their language and prosecution records may differ. The final assessment should explain which technical facts and prosecution events support the conclusion, and which product changes would require revisiting it.
The doctrine's practical importance therefore begins before litigation. Applicants can preserve useful options through supported drafting and careful prosecution. Competitors can make more dependable design decisions by examining the record behind the claim language. Across the jurisdictions considered here, the central professional task is to explain both why the substitute is technically significant and what legal effect the patent's drafting and prosecution history give that significance.
